Amicus Therapeutics Announces Presentations at the 26th International Annual Congress of the World Muscle Society

Rhea-AI Summary

Amicus Therapeutics (Nasdaq: FOLD) presented two posters at the 26th International Annual Congress of the World Muscle Society, held from September 20-24, 2021. The posters highlight the company’s development program for Pompe disease, including a study comparing cipaglucosidase alfa/miglustat with alglucosidase alfa/placebo in late-onset Pompe disease. The investigational therapy is not yet approved by regulatory agencies. Details on the presentations will be available on Amicus's website following the congress.

Positive

• Presentation at a major international conference showcases ongoing research in Pompe disease.
• Focus on innovative therapy could enhance Amicus's reputation in the biotechnology sector.

Negative

• Cipaglucosidase alfa/miglustat remains an investigational therapy, lacking regulatory approval.

PHILADELPHIA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced two posters for presentation highlighting its development program for Pompe disease at the 26th International Annual Congress of the World Muscle Society (WMS) being held virtually, September 20-24, 2021.

ePoster Presentations:

• Cipaglucosidase alfa/miglustat versus alglucosidase alfa/placebo in late-onset Pompe disease: PROPEL study subgroup analyses
  • Presenter: Mark Roberts, MD, Consultant Neurologist, Salford Royal NHS Foundation Trust, Greater Manchester Neurosciences Centre, United Kingdom (ePoster #196)

• Living with late-onset Pompe disease in the UK: interim results characterising the patient journey and burden on physical, emotional and social quality of life
  • Presenter: Allan Muir, Chair of the Board of Trustees, Pompe Support Network, United Kingdom (ePoster #201)

Cipaglucosidase alfa/miglustat is an investigational therapy that is not yet approved by any regulatory agency.

The posters will be made available on the Amicus website following their respective presentations at the congress.

For more information on the 26^th International Annual Congress of the World Muscle Society, please visit www.wms2021.com.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare metabolic diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a robust pipeline of cutting-edge, first- or best-in-class medicines for rare metabolic diseases. For more information please visit the company’s website at www.amicusrx.com, and follow us on Twitter and LinkedIn.

CONTACT:

Investors:
Andrew Faughnan
Executive Director, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G

FAQ

What was presented by Amicus Therapeutics at the World Muscle Society Congress 2021?

Amicus Therapeutics presented two posters focusing on its development program for Pompe disease.

What is the investigational therapy being discussed in the Amicus Therapeutics presentation?

The investigational therapy discussed is cipaglucosidase alfa/miglustat.

When is the World Muscle Society Congress 2021 taking place?

The World Muscle Society Congress 2021 is being held from September 20-24, 2021.

Is cipaglucosidase alfa/miglustat approved by regulatory agencies?

No, cipaglucosidase alfa/miglustat is not yet approved by any regulatory agency.